Trial Profile
An international, multicenter, open-label, one-arm study in 150 infants vaccinated with a 3-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine in the Russian Federation and Poland.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 26 Nov 2016 Status changed from recruiting to completed.
- 07 Oct 2015 New trial record